Focus: Santen is a specialty biotechnology company focused exclusively on ophthalmology, headquartered in Emeryville, CA with a diversified portfolio of marketed and pipeline ophthalmic products.
Profile data last refreshed 4h ago · AI intelligence enriched 1w ago
Hot — 156 jobs added in 30d
Net +132 (156 new, 24 removed). Aggressive expansion phase.
Best for ophthalmology-focused scientists and development professionals seeking deep therapeutic expertise in a scaling specialty biotech with meaningful pipeline depth, but limited visibility into financial health.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Fluoroquinolone ophthalmic antibiotic facing generic competition.
Help build intelligence for Santen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Santen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-generation fluoroquinolone formulation nearing loss of exclusivity.
Mast cell stabilizer for allergic conjunctivitis approaching patent expiration.
Santen Pharmaceutical Co., Ltd. Financial Disclosures & Filings - TradingView
Santen Pharmaceutical Co., Ltd. Financial Disclosures & Filings TradingView
Santen to Dispose of Treasury Shares for Performance-Linked Executive Stock Plan - TipRanks
Santen to Dispose of Treasury Shares for Performance-Linked Executive Stock Plan TipRanks
Total liabilities & shareholders' equities of Santen Pharmaceutical Co., Ltd. – HAM:SZD - TradingView
Total liabilities & shareholders' equities of Santen Pharmaceutical Co., Ltd. – HAM:SZD TradingView
ETFs Investing in Santen Pharmaceutical Co., Ltd. Stocks - TradingView
ETFs Investing in Santen Pharmaceutical Co., Ltd. Stocks TradingView
Santen Pharmaceutical Co., Ltd. Income Statement – HAM:SZD - TradingView
Santen Pharmaceutical Co., Ltd. Income Statement – HAM:SZD TradingView
SZD Stock Price and Chart — HAM:SZD - TradingView
SZD Stock Price and Chart — HAM:SZD TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study.
Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo